We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves AbbVie’s Humira to Treat Pediatric Crohn’s Disease Patients
FDA Approves AbbVie’s Humira to Treat Pediatric Crohn’s Disease Patients
With patent expirations looming, AbbVie secured a new indication for its blockbuster biologic Humira to treat children suffering from moderate to severe Crohn’s disease.